The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 32, No. 1, pp. S22-26.
© 1998 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramirez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramirez, J.

Research Articles

Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia

JA Ramirez

BACKGROUND: Antimicrobial drugs are prescribed inappropriately nearly 50% of the time. To address this problem, a hospital antimicrobial team was formed integrating the talents of infectious disease physicians, pharmacists, microbiologists, infectious control practitioners, and nurses. The primary goal of the team is to provide optimal, cost-effective antimicrobial therapy. OBJECTIVE: To review the principles of streamlining antimicrobial therapy, with an emphasis on antibiotic switch therapy. DISCUSSION: With appropriate guidelines, switch therapy appears to be an important means to provide optimal antimicrobial therapy complementing the many social pressures placed on patients, while positively impacting on the overall cost of treatment. The use of beta-lactam/beta-lactamase inhibitor combinations as the antibiotics for initial intravenous medication to oral combination switch therapy is a viable approach to the treatment of hospitalized patients with community-acquired pneumonia. Preliminary data from our institution were obtained with such a therapeutic approach to assess the clinical efficacy, patient satisfaction with their care, and calculated dollar savings in the overall cost of care. The results of this evaluation strongly support the validity and desirability of such an approach. CONCLUSIONS: The prospective use of a program that incorporates the use of beta-lactam/beta-lactamase inhibitor combinations for intravenous and switch-to-oral drug administration is a cost-effective means of providing optimal antimicrobial therapy for patients with community-acquired pneumonia.


This article has been cited by other articles:


Home page
 American Journal of Medical QualityHome page
J. T. Hagaman, P. Yurkowski, A. Trott, and G. W. Rouan
Getting Physicians to Make "The Switch": The Role of Clinical Guidelines in the Management of Community-Acquired Pneumonia
American Journal of Medical Quality, January 1, 2005; 20(1): 15 - 21.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
J-B. Wasserfallen, V. Erard, A. Cometta, T. Calandra, and O. Lamy
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Eur. Respir. J., October 1, 2004; 24(4): 644 - 648.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. G. Campbell, T. J. Marrie, R. Anstey, G. Dickinson, and S. Ackroyd-Stolarz
The Contribution of Blood Cultures to the Clinical Management of Adult Patients Admitted to the Hospital With Community-Acquired Pneumonia: A Prospective Observational Study
Chest, April 1, 2003; 123(4): 1142 - 1150.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1998 by Harvey Whitney Books Company.